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Background: Benzene is an established human leukemogen, with a ubiquitous environmental presence leading to
significant population exposure. In a genome-wide functional screen in the yeast Saccharomyces cerevisiae,
inactivation of IRA2, a yeast ortholog of the human tumor suppressor gene NF1 (Neurofibromin), enhanced
sensitivity to hydroquinone, an important benzene metabolite. Increased Ras signaling is implicated as a causal
factor in the increased pre-disposition to leukemia of individuals with mutations in NF1.
Methods: Growth inhibition of yeast by hydroquinone was assessed in mutant strains exhibiting varying levels of
Ras activity. Subsequently, effects of hydroquinone on both genotoxicity (measured by micronucleus formation)
and proliferation of WT and Nf1 null murine hematopoietic precursors were assessed.
Results: Here we show that the Ras status of both yeast and mammalian cells modulates hydroquinone toxicity,
indicating potential synergy between Ras signaling and benzene toxicity. Specifically, enhanced Ras signaling
increases both hydroquinone-mediated growth inhibition in yeast and genotoxicity in mammalian hematopoetic
precursors as measured by an in vitro erythroid micronucleus assay. Hydroquinone also increases proliferation of
CFU-GM progenitor cells in mice with Nf1 null bone marrow relative to WT, the same cell type associated with
benzene-associated leukemia.
Conclusions: Together our findings show that hydroquinone toxicity is modulated by Ras signaling. Individuals
with abnormal Ras signaling could be more vulnerable to developing myeloid diseases after exposure to benzene.
We note that hydroquinone is used cosmetically as a skin-bleaching agent, including by individuals with cafe-au-lait
spots (which may be present in individuals with neurofibromatosis who have a mutation in NF1), which could be
unadvisable given our findings.
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Benzene is ubiquitous in the environment due to its
wide use in industry for the production of plastics,
resins, dyes and detergents, and its presence in gasoline.
Hydroquinone (HQ) is a primary oxidative metabolite of
benzene. Globally, there is extensive population and oc-
cupational exposure to HQ [1]. Both benzene and HQ
are also found in cigarette smoke and HQ is the most* Correspondence: vulpe@berkeley.edu
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reproduction in any medium, provided the orabundant pro-oxidant compound in cigarette smoke tar
[2], though HQ is also found in the plasma of nonsmoker
individuals living a Western lifestyle [3]. In addition to
industrial exposure, there is significant dietary exposure
to HQ in the form of arbutin, a HQ glucose conjugate
[3]. Also, in some individuals dermal exposure can be
significant as HQ is used as a skin-bleaching agent, to
treat conditions such as hypermelanosis, vitiligo, and
cafe-au-lait spots.
Benzene causes leukemia in humans (reviewed in [1])
and HQ itself causes DNA damage in vitro. HQ is capable
of binding to both DNA and protein, and can inducetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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through a multi-step process involving the action of
Cytochrome P450s on benzene in the liver and perhaps
other organs. HQ can travel to the bone marrow and is
oxidized through both autoxidation and by myeloper-
oxidase (MPO) to highly toxic quinones [7], thus con-
tributing significantly to benzene toxicity.
Ras proteins transduce cellular signals required for the
control of cell growth and differentiation [8], and activat-
ing Ras mutations are present in ~30% of cancers [9,10].
The ERK effector kinases of the Ras/MAPK pathway mod-
ify diverse substrates which ultimately mediate cellular
pathways controlling cell growth [11]. In a genome-wide
functional screen using the yeast Saccharomyces cerevisiae,
we previously identified IRA2 as required for cellular
tolerance to HQ treatment [6]. Ira2p is a Ras GTPase
activating protein (GAP) that stimulates conversion of
Ras proteins from their active GTP-bound state to the
inactive GDP-bound state. Deletion of IRA2 results in
an increase in active Ras (and thus Ras signaling). Hetero-
zygous germline mutations in NF1, the human homolog
of IRA2, cause neurofibromatosis type I (NF1), a common
developmental disorder with an incidence of 1 in 3000 live
births [12]. NF1 belongs to a group of disorders referred
to as the RASopathies (reviewed in [12]), caused by germ-
line mutations in components of the RAS/MAPK pathway
that all give rise to an increased cancer risk [12]. Individ-
uals with NF1 are predisposed to benign and malignant
tumors, which typically arise in cells derived from the
embryonic neural crest [13,14]. Children with NF1 have a
200–500 fold risk of developing juvenile myelomonocytic
leukemia (JMML), an aggressive myeloproliferative disorder
(MPD) [15]. Consistent with its biochemical activity as
a negative regulator of Ras signaling, JMML and other
NF1-associated neoplasms frequently show somatic in-
activation or the normal NF1 allele [13,16]. Patients with
NF1 are also at increased risk of developing myeloid
leukemia and other genotoxin-induced malignancies
[17], and homozygous mutations in NF1 were recently
reported in a subset of adult acute myelogenous leukemias
(AML) [14].
Homozygous inactivation of a conditional mutant allele
of murine Nf1 in the hematopoietic compartment results in
a progressive MPD that models JMML [18]. Heterozygous
Nf1 mutant mice are also susceptible to myelodysplastic
syndrome (MDS) and other genotoxin-induced cancers,
and appear to be particularly sensitive to the mutagenic
effects of radiation [19,20]. As with IRA2 in yeast, NF1
mutations lead to hyperactive Ras signaling [21,22], and are
consistent with the high prevalence of somatic NRAS
and KRAS mutations in these cancers. The association
between hyperactive Ras signaling and leukemogenesis
is particularly compelling in JMML and chronic myelomo-
nocytic leukemia (reviewed in [9,23]).Altered regulation of Ras signaling and exposure to
benzene and its metabolites are both leukemogenic, but
the sensitivity of ira2Δ to HQ represents, to our know-
ledge, the first observation of a potential synergism. Other
examples of synergism between exogenous compounds
and altered Ras signaling include the observation that lung
carcinomas induced by cumene (a compound structurally
similar to HQ) have greater malignant potential in mice
with K-ras mutations [24], and also that benzene-induced
mammary tumors in mice show an increased frequency of
H-ras mutations [25]. However, an association between
Ras signaling status and HQ toxicity has not been previ-
ously defined. Here we report our study demonstrating
the interaction of mutations in both IRA2 in yeast and Nf1
in murine hematopoietic cells with the cellular conse-
quences of HQ exposure.
Results
Modulation of Ras signaling in yeast alters the toxicity of
hydroquinone
IRA2 was previously identified in a genome-wide screen
for genes required for HQ tolerance [6] and sensitivity
to HQ was confirmed by analysis of the individual deletion
strain (Figure 1A). IRA2 is orthologous to the human
tumor suppressor gene NF1, and expression of the human
neurofibromin catalytic domain (GRD) in yeast recovers
the phenotype of ira2Δ cells [26]. As Ira2p is a negative
regulator of Ras (i.e. its deletion leads to increased Ras
signaling due to decreased turnover of active-Ras) we
tested other mutants in the Ras pathway that have altered
signaling. Yeast has two Ras proteins, Ras1p and Ras2p,
which are highly homologous to their mammalian coun-
terparts. They exhibit some functional redundancy, like
many S. cerevisiae paralogs, though Ras1p is specialized
for proliferation-related signaling, whereas Ras2p regulates
complex cellular differentiation (i.e. sporulation and fila-
mentation) in response to nutrient starvation (reviewed in
[27]). Deletion of RAS1 results in increased tolerance to
HQ treatment, whereas deletion of RAS2 has no effect
(Figure 1B, 1C and Additional file 1: Figure S1). To pro-
vide further mechanistic evidence for this observation that
Ras signaling (through Ras1p) modulates HQ toxicity, we
examined a RAS1 overexpression strain, and this strain
also exhibits increased sensitivity to HQ (Figure 1D).
Increased genotoxicity is seen in murine bone marrow
cells lacking Nf1 following HQ treatment
To determine if there was an influence of Nf1 on DNA
damage by HQ in mouse bone marrow cells, we assessed
micronucleus (MN) formation using an in vitro erythroid
MN assay [28]. Micronuclei are small fragments of nuclear
membrane-encapsulated DNA formed by enucleation of
cells with DNA damage during erythropoiesis. Measuring
their presence in vitro can be used to sensitively detect
Figure 1 The Ras status of yeast cells modulates the toxicity of HQ. The Area Under Curve (AUC) was calculated for each strain after 24 h of
exposure to the indicated doses of HQ. The bars represent mean AUC as a percentage of the untreated for each strain with standard error of
three replicates. Sensitivity was determined by comparison to the wild type strain (gray bars = wild type; white bars = indicated deletion/
overexpression strain). A ira2Δ (increased Ras signaling) is sensitive to HQ. B ras1Δ (reduced Ras signaling) is resistant to HQ. C ras2Δ showed a
response to HQ equivalent to WT. D Overexpression of RAS1 (increased Ras signaling) results in sensitivity to HQ.
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than other in vivo methods, while allowing for testing at
an increased number of doses [28]. Nf1 null mice die in
utero, thus a Cre/loxP system was used to generate a
conditional allele (Nf1 flox) at the Nf1 locus, resulting
in ablation of neurofibromin in hematopoietic tissues
following the induction of Cre expression using interferon
gamma [18].
We first established that HQ can induce MN in vitro
as it does in the in vivo mammalian MN assay [29], and
determined the appropriate dose range. Lineage-marker-
negative (Lin-) BM was used as a starting population for
in vitro erythropoietic MN experiments, and terminal
erythropoiesis progressed normally as assayed by flow
cytometry and histological examination (data not shown).
Cultures were treated with HQ for 1 hour, starting 23
hours after seeding, and progressed normally through
erythropoiesis. MN-PCEs appeared in both treated cul-
tures and controls, but with greater frequency in treated
cultures (Figure 2A).Lin- BM from Nf1 mutant mice and their WT litter-
mates was then used to test whether the Nf1−/− genotype
affected genotoxic sensitivity to HQ. There was a higher
recovery of Lin- BM cells from the Nf1−/− mice (0.7%) than
the WT littermates (0.3%). The greater recovery of Lin-
BM cells in the Nf1−/− mice is likely indicative of chronic
polyclonal hyperproliferation due to hypersensitivity to
GM-CSF, which is mediated by increased and prolonged
Ras activation [30]. Regardless, upon culturing, erythro-
poietic differentiation in Nf1−/− cultures was indistinguish-
able from that of WT littermates. The MN frequencies
observed in vitro for both the negative controls and the
treated cultures were higher than the levels typically
observed in vivo [19,20]. This increase may be caused by
the relatively high rate of erythropoietic growth and lack
of spleen function in vitro; increasing erythropoietic rates
in vivo through bleeding [31] or exogenous erythropoietin
(EPO) expression increases erythroid MN frequencies and
has been shown to sensitize the in vivo assay to genotoxic
exposure [32]. Cell viability at harvest was >85% for all
Figure 2 Detection of genotoxicity through in vitro erythropoiesis. A Representative micrograph of Day 2 harvested cultures at 100x
magnification. The arrows indicate normally enucleated PCEs, and the arrowhead indicates a micronucleated PCE. Scale bar = 8 μM. B Nf1−/−
Lin- BM cultures exhibit sensitivity to MN formation after in vitro exposure to HQ. The response of this erythropoietic culture system to HQ
treatment is quantified by MN frequency in PCEs. Data presented is the mean of the “n” independent cultures ± SD.
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control (data not shown). Cell proliferation and death
were not explicitly measured, thus reductions in viable cell
yields cannot be specifically attributed to cytotoxic or
cytostatic mechanisms.
Both Nf1−/− and WT cultures treated with hydroquin-
one at 50 μM, 75 μM, and 100 μM showed a significant
dose-dependent increase (two-tailed unequal variance
t-test, p < 0.05) in MN formation compared to the re-
spective controls (Figure 2B – significance not indicated).
A two-way ANOVA analysis found that there was an over-
all significant difference between the MN frequency found
in the Nf1−/− cultures and the corresponding WT cultures
(p < 0.001). A two-tailed unequal variance Student’s t-test
was employed to examine the differences at each dose.
There was no significant difference in MN formation
between the untreated cultures (p = 0.87) but there was
a significantly greater induction of MN in the Nf1−/−
cultures than the WT cultures at both 50 μM (p < 0.01)
and 100 μM (p < 0.05) (Figure 2B). This observation
indicates that increased Ras signaling increases the
genotoxicity of HQ.
Murine bone marrow progenitor cells lacking Nf1 show
increased proliferation relative to WT following treatment
with HQ
To further investigate the possible role of Nf1 in devel-
opment of hematological malignancies such as leukemia
following exposure to HQ, we measured the prolifera-
tive ability of myeloid hematopoietic progenitor cells
after treatment. We assayed CFU-GM colony growth at
several HQ dosage levels for WT and Nf1−/− bone marrow
cells and normalized this data to the untreated controls
(Figure 3). HQ caused a dose-dependent decrease in theproliferative ability of progenitor cells in both WT and
Nf1−/− cells, in agreement with a previous study [33]. In
both genotypes, colony formation was reduced upon ex-
posure to as little as 10 μM HQ, and CFU-GM numbers
continued to fall with increasing HQ exposure up to
30 μM HQ treatment (Figure 3). At higher doses of HQ
(e.g. 100 μM), all colony formation was prevented by ex-
cessive toxicity to both genotypes (data not shown). Un-
expectedly, Nf1−/− progenitors demonstrated significantly
increased survival to HQ exposure in comparison to WT
(Figure 3) at 10 μM [p-value 0.0010]. We cannot ascribe
these apparent differences to MPD in the Nf1−/− mice
because the inhibitory effects of HQ were normalized to
growth in the absence of HQ for both genotypes. More-
over, the Nf1−/− mice were euthanized at a relatively young
age (12 weeks) and showed no overt evidence of myeloid
disease as assessed by complete blood counts conducted
on the harvest BM (data not shown). Thus, the difference
observed is likely driven specifically by the HQ treatment.
Discussion
Hydroquinone (HQ) is a benzene metabolite, component
of cigarette smoke, and skin-bleaching agent. A genome-
wide functional screen in the yeast Saccharomyces cerevi-
siae identified IRA2 as required for tolerance to treatment
with HQ.
IRA2 is a yeast ortholog of the human tumor suppressor
gene NF1, mutations in which cause the disease neuro-
fibromatosis type I (NF1). Affected individuals are pre-
disposed to developing cancers, including leukemia, due
to increased Ras signaling [13]. The Ras protein family
is involved in signal transduction, and their activation
leads to growth, differentiation and cellular survival.
NF1 has been recently identified as important in the
Figure 3 Nf1−/− hematopoietic progenitors of the granulocyte and macrophage lineages are resistant to HQ-induced toxicity. CFU-GM
colony counts, relative to untreated controls, are plotted vs. HQ exposure level for cultures derived from both WT and Nf1−/− BM. Bone marrow
cells from each genotype were treated with HQ in MethoCult® capable of inducing growth of CFU-GM colonies and then cultured for 12 days. In
both genotypes colony formation was reduced upon exposure to as little as 10 μM HQ. CFU-GM numbers continued to fall with increasing HQ
exposure up to 30 μM HQ treatment, and at all doses the Nf1−/− BM appeared resistant to HQ-induced toxicity when compared with BM from
WT littermates.
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the same form of leukemia that is associated with expos-
ure to benzene, an established human leukemogen. How-
ever, the association between Ras status and HQ toxicity
has not been defined. Our previous identification of IRA2
as required for HQ tolerance was the first observation of a
potential synergism between Ras signaling and the toxicity
of benzene. To gain further insight into this association
we investigated the requirement of both IRA2 in yeast and
Nf1 in murine hematopoietic cells for the response to HQ.
The sensitivity of yeast cells lacking IRA2 to HQ was
confirmed by analysis of the ira2Δ deletion strain. We
found that while ira2Δ cells with increased levels of
active Ras were more sensitive to HQ treatment, ras1Δ
cells with decreased active Ras were less sensitive, and
actually showed resistance to HQ. Consistent with these
data, we also found that cells overexpressing RAS1 (effect-
ively phenocopying ira2Δ) show increased sensitivity to
HQ. This confirmed that ira2Δ HQ sensitivity is not due
to a specific property of Ira2p and provides substantial
support for our hypothesis that the level of active Ras
signaling modulates the toxicity of HQ.
How could increased Ras signaling cause an increase
in HQ toxicity? The observation that modulation of HQ
toxicity is specific to signaling through Ras1p (ras2Δ
showed a response to HQ equivalent to WT) provides a
potential explanation. Ras1p regulates progression of the
cell cycle, and an increase in cell cycle rate could explain
increased HQ toxicity. HQ has multiple cellular targets in
yeast, including the cytoskeleton and vesicular transport,and it generates oxidative stress, causes lipid peroxidation
and damages DNA [6]. The deleterious effects of these
processes could be amplified in the context of increased
cell cycle rate, and so would result in an increase in
growth inhibition.
In order to study the significance of our findings in
human health, we studied the relationship between Nf1
and HQ tolerance in a murine model. We determined
that the Nf1−/− genotype renders mammalian bone mar-
row progenitor cells more sensitive to genotoxic damage
by HQ, as measured by an increase in micronuclei forma-
tion. We have shown that HQ treatment causes a dose-
dependent decrease in the number of CFU-GM colonies
derived from both WT and Nf1−/− progenitors. However,
in contrast to the yeast studies, HQ treated Nf1−/− cell
showed increased proliferation in comparison to wild type
cells. Our work and previous studies showed that un-
treated Nf1−/− cells show increased proliferation due to
hyperactive Ras [34], but even after normalization for this
effect, HQ treatment at the doses used further increased
proliferation of WT progenitors. We therefore propose
that null cells may more rapidly divide down the differen-
tiation lineages than WT (regardless of damage), and this
higher proliferation of damaged cells could explain the
greater MN frequency. By both increasing genetic damage
and enhancing survival in Nf1 mutant hematopoietic cells,
HQ could facilitate the development of myeloid malignan-
cies such as MDS and AML.
One possible explanation for this increased relative
growth is that HQ could stimulate GM progenitor growth
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this idea comes from the observation that HQ stimulates
GM-CSF-dependent proliferation of erythroleukemia cells
and human CD34+ bone marrow cells via activation of
ERK [35]. As noted above, in primary Nf1−/− progenitor
cells there is constitutive activation of Ras [34]. GM-CSF
[34] mediates an increased and prolonged Ras activation
[30] and Nf1−/− cells, unable to modulate this effect, are
hypersensitive to GM-CSF. Further, HQ acts synergistic-
ally with GM-CSF to induce proliferation of progenitor
cells that would not normally be recruited by the cytokine
[36]. Deletion of Nf1 potentiates this effect due to in-
creased Ras activation. Interestingly, 1,4-BQ (from HQ)
also induces activation of ERK1 and ERK2 [37] in rat liver
epithelial cells so it is possible that HQ could have a simi-
lar effect in bone marrow cells. Similarly, the hyperactive
Ras effect of Nf1−/− on erythroid progenitors acts specific-
ally through the ERK pathway and not through other
pathways regulated by Ras [38]. We therefore suggest
that the combination of hyper-sensitization to GM-CSF
in Nf1−/− cells and activation of ERK by HQ could
explain the increased proliferation of null cells relative
to WT following HQ treatment. Alternatively or in
addition, DNA damage caused by HQ may stimulate
proliferation of GM progenitors in Nf1−/− cells via p53
dependent mechanisms. Previous work found that the
genotoxin cytarabine causes increased myeloid differen-
tiation in bone marrow cells with a Ras mutation via a
p53-dependent mechanism [39].
Conclusions
Together our findings show that HQ toxicity is modu-
lated by Ras signaling and that increased Ras signaling
(by deleting Nf1) results in both an increased level of
DNA damage detected in erythroid progenitors and in-
creased survival of GM progenitors. HQ exposure and
pre-existing increased Ras signaling could increase the
likelihood of leukemic transformation. Importantly, our
observations with HQ are highly consistent with obser-
vations in human patients and in mice showing that
heterozygous Nf1 inactivation cooperates strongly with
genotoxins (particularly radiation) to induce myeloid
malignancies and other secondary cancers [17,19]. In
addition to NF1, individuals with Noonan syndrome
and other RASopathies could be more vulnerable to devel-
oping myeloid diseases after exposure to benzene. Of
particular concern is the use of hydroquinone as a skin-
lightening agent by NF1 patients. HQ is given to NF1 pa-
tients to treat the characteristic cafe-au-lait pigmentation
spots, which are a key diagnostic criterion of NF1. Our
work indicates that the interaction between Ras signaling,
sensitivity to toxicants, and the development of neoplasia
needs to be given further consideration. Such studies may
aid in the development of more protective standards forsensitive individuals to occupational and public exposures
to carcinogens such as benzene.
Methods
Yeast strains and culture
Diploid yeast deletion strains used for growth analyses
were of the BY4743 background (MATa/MATα, his3Δ1/
his3Δ1, leu2Δ0/leu2Δ0, lysΔ0/LYS2, MET15/met15Δ0,
ura3Δ0/ura3Δ0, Invitrogen Corporation, Carlsbad, CA).
The haploid yeast MORF (Movable ORF - [40]) strain
for RAS1 overexpression was of the Y258 background
(MATa, pep4-3, his4-580, ura3-53, leu2-3,112 - Thermo
Fisher Scientific Open Biosystems, Huntsville, AL).
Growth was conducted in liquid rich media (1% yeast ex-
tract, 2% peptone, 2% dextrose, YPD) for deletion strain
growth curve assays, and liquid synthetic complete media
lacking uracil (SC-ura) using either 2% dextrose or 2% raf-
finose as a carbon source for pre-growths of the overex-
pression strain for growth curve assays (detailed below).
Liquid rich media for induction of protein overexpression
for growth curve assays contained both galactose and
raffinose (1% yeast extract, 2% peptone, 2% galactose,
2% raffinose, YPGal + Raf ).
Yeast hydroquinone exposures
Hydroquinone (HQ) (Sigma-Aldrich, St Louis, MO)
stock solutions were prepared fresh in sterile nuclease-free
water (ISC BioExpress, Kaysville, UT) and protected from
light.
Yeast deletion strain growth curve assays
Yeast strains were pre-grown to mid-log phase, diluted
to an optical density at 600 nm (OD600) of 0.0165, and
dispensed into individual wells of a 48-well plate (non-
treated polystyrene, Grenier Bio-One, Monroe, NC). HQ
stock solution was added to the desired final concentra-
tions with at least two replicates per dose. Plates were
incubated in a GENios microplate reader (Tecan, Durham,
NC) set to 30°C with intermittent shaking. OD595 mea-
surements were taken at 15-minute intervals for a period
of 24 hours. Raw absorbance data were averaged for all
replicates, background corrected, and plotted as a function
of time. The area under the curve (AUC), used as a meas-
ure of growth, was calculated with Excel 2008 (Microsoft
Corporation, Redmond, WA) and expressed as a per-
centage of the control. AUCs were compared with two-
way ANOVA followed by Bonferroni post-tests, using
GraphPad Prism version 5.01 (GraphPad Software, La
Jolla, CA). Data for each strain is derived from three
independent biological replicates.
Yeast RAS1 overexpression strain growth curve assays
The yeast RAS1 overexpression strain was pre-grown
overnight to stationary phase in SC-ura 2% dextrose,
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night again to alleviate glucose repression. Cells were
then diluted in YPGal + Raf to induce protein overex-
pression, and grown for 5 hours to mid-log phase. Cells
were subsequently diluted to an optical density at
600 nm (OD600) of 0.0165 in YPGal + Raf, and dispensed
into wells of a 48-well plate. Hydroquinone treatment,
plate measurement and data processing were all carried
out in the same manner as for the deletion strain growth
curve assays.
Mice
Mx1-Cre, Nf1flox/flox mice (129SV × C57BL/6 J) were
generated and somatic Nf1 inactivation was induced as
described elsewhere [18]. We refer to hematopoietic
cells from these animals as Nf1−/− throughout this paper.
Cells from wild type (WT) littermates were used as con-
trols in all experiments. Mice were maintained in the
sterile animal care facility at the University of California,
San Francisco (UCSF), and were fed pelleted chow and
acidified water ad libitum. All experimental procedures
involving mice were approved by the UCSF Committee
on Animal Research.
Murine cells
Tissue was harvested from mice at ~12 weeks. Bone
marrow (BM) cells were isolated from the hind legs and
were mechanically dissociated by pipetting in Iscove’s
modified Dulbecco’s medium (IMDM) with L-glutamine/
4% FBS (IMDM – Lonza, Walkersville, MD). Single-cell
suspensions were prepared by passing dissociated cells
through 70 μm cell strainers. BM cells were counted using
a hemocytometer.
Erythropoietic culture
Total BM cells were labeled with biotin-conjugated α-Lin
Abs, consisting of α -CD3e, α -CD11b, α -CD45R/B220,
α -Ly6G/Ly6C, and α -TER-119 Abs (2 μl of each Ab/106
cells; BD Pharmingen, San Diego, CA), and Lineage-
marker-negative (Lin-) cells were purified through a 0.3-in
StemSep negative selection column as per the manufac-
turer’s instructions (StemCell Technologies, Vancouver,
BC, Canada). Purified cells were seeded in fibronectin-
coated (2 μg/cm2) tissue culture treated 24-well polystyr-
ene plates (BD Falcon, BD Biosciences San Jose, CA) at a
cell density of 105 cells/ml. On the first day, purified cells
were cultured in IMDM containing basal supplements
consisting of: 15% FBS, 1% detoxified BSA, 200 μg/ml
holotransferrin (Sigma, St Louis, MO), 10 μg/ml recom-
binant human insulin (Sigma), 10-4 M β-mercaptoethanol,
50 units/ml penicillin G, and 50 μg/ml streptomycin; as
well as soluble erythropoietic factors including erythropoi-
etin (Epo - Amgen, Thousand Oaks, CA) at 7.5 units/ml
and stem cell factor (SCF - R & D Systems, Minneapolis,MN) at 10 ng/ml. For all cultures, media was replaced
with erythroid-differentiation medium (EDM) (IMDM
with 20% FBS, and 10-4 M β-mercaptoethanol) after 1 day
of culture. At harvest, suspended cells were removed from
culture wells by pipetting, and the culture well was then
incubated in PBS/10% FBS/5 mM EDTA for 5 minutes at
37°C to dissociate adherent cells. Dissociated cells were
then removed from the culture well by pipetting and com-
bined with the suspended cell fraction from the same cul-
ture well for analysis. Viable cell counts, based on trypan
blue exclusion, were conducted using a hemocytometer.Genotoxic treatment of erythropoietic cultures
Lin- BM was cultured in 500 μl of medium per culture
well according to the method described for erythropoietic
culture. Cultures were treated one hour before being
washed and fed with EDM, as earlier described. HQ so-
lutions were prepared immediately before treatment
and protected from light to minimize degradation and
decreased reactivity. HQ (Sigma) was first dissolved in
warm PBS to make a 10 mM stock solution. This
10 mM solution was diluted in 4°C PBS to produce
7.575 mM and 5.05 mM solutions, and 5 μl of a solution
was added to each culture to expose them to the tar-
geted concentrations of HQ (100 μM, 75 μM, and
50 μM).Cytospin preparation and cytological staining
Approximately 2×104 cells per culture were centrifuged
onto slides for 2 minutes at 800 rpm (Statspin Cytofuge
2; Iris Sample Processing Westwood, MA) and air-dried.
For acridine orange staining, cells were fixed in 25°C
methanol for 10 minutes and stained in acridine orange
(Sigma) at a concentration of 20 μg/ml in staining buffer
(19 mM NaH2PO4 and 81 mM Na2HPO4) for 10 minutes
at 4°C. Following acridine orange staining, slides were
protected from light, washed for 10 minutes in 4°C stain-
ing buffer, air-dried, and stored at 4°C until microscopic
examination and scoring was complete.Histological imaging and quantification
Slides were examined by using an Axioplan 2 microscope
(Carl Zeiss MicroImaging GmbH, Germany) and repre-
sentative micrographs were acquired by using Axiocam
MRm (Carl Zeiss). Micrographs of acridine orange stained
cells were acquired by using a 63x oil-immersion objective
and fluorescence (100 W Hg lamp excitation). Cytological
slides were examined blind, and differential cell counting
was used to enumerate relevant cell types and thus
quantify the frequency of micronucleated polychromatic
erythrocytes (MN-PCEs) among total PCEs (>2,000 PCEs
scored per slide).
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To determine the statistical significance of mean compari-
sons, distributions were first checked for normality by
using the Shapiro–Wilk's test with STATA 11 (StataCorp,
College Station, TX). Normal data sets were then
subjected to two-way ANOVA analysis. Interaction
between dose and breed was examined but found to be
insignificant and so was not used in the model. Two-
tailed Student’s t tests were executed by using the data
analysis tool in Excel (Microsoft Corporation, Redmond,
WA). Unequal variance was assumed to increase confi-
dence in significant p-values.
Progenitor assays
Colony forming unit granulocyte/macrophage (CFU-GM)
progenitors were grown in MethoCult® (StemCell Tech-
nologies, Cat #03434) according to manufacturer’s instruc-
tions (Technical Manual Cat# 28405). Briefly, BM cells
were suspended at 4×105/ml in IMDM/2% FBS and then
200 μl of this suspension was added to 4 ml aliquots of
MethoCult® M3434, which were then vortexed briefly. A
fresh solution of 10 mM HQ (Sigma) was then prepared in
warm PBS and sterile filtered through a 0.2 μm membrane
(Pall Life Sciences, Ann Arbor, MI). This 10 mM HQ stock
solution was then further diluted to give 600 μM, 400 μM,
and 200 μM solutions, and then 200ul of one of these solu-
tions was used to treat each 4 ml aliquot of MethoCult® at
a concentration of 30 μM, 20 μM, or 10 μM. After delivery
of HQ, the MethoCult® was again vortexed briefly and the
tubes were left to stand for 5 minutes to allow bubbles to
dissipate. A 16G blunt-end needle and 3 ml syringe were
then used to draw up the treated MethoCult® and dispense
1.1 ml into each of three 35 mm petri dishes (StemCell
Technologies, Cat# 27100). These 35 mm culture dishes
(3 per genotype/treatment replicate) were then tilted and
rotated gently to evenly distribute MethoCult® and placed
in a 100 mm culture dish that also contained an uncov-
ered 35 mm culture dish containing 3 ml of sterile water
to maintain humidity. The cultures were placed in an in-
cubator and maintained at 37°C, 5% CO2 in air, and >95%
humidity for 12 days, then colonies were scored. The scor-
ing scientist was blinded to the identity of each culture
(genotype/treatment). Two independent preparations
of each culture condition (combination of genotype/
treatment) were used in each trial, and the entire experi-
ment was repeated three further times using independent
sets of Nf1−/−/WT littermates.
Additional file
Additional file 1: Figure S1. ras2Δ is significantly more sensitive to HQ
than ras1Δ. The Area Under Curve (AUC) was calculated for each strain
after 24 h of exposure to the indicated doses of HQ. The bars represent
mean AUC as a percentage of the untreated for each strain withstandard error of three replicates. Sensitivity was determined by
comparison to the wild type strain (gray bars = ras1Δ; white bars = ras2Δ).Competing interests
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